Is BSX a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Farapulse and the Pulsed Field Ablation Wave, with revenue (ttm) at ~$20.6 billion. The bear case rests on the most immediate concern flagged with 2026 guidance was unanticipated headwinds in electrophysiology, Watchman, and urology, which prompted management to frame organic growth guidance of 6.5% to 8%, below the pace of recent years and a signal that the newest franchises may be decelerating from peak growth rates. Analysts covering it are spread from $55.00 to $106.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The most immediate concern flagged with 2026 guidance was unanticipated headwinds in electrophysiology, Watchman, and urology, which prompted management to frame organic growth guidance of 6.5% to 8%, below the pace of recent years and a signal that the newest franchises may be decelerating from peak growth rates. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $55.00, +18.5% from the $46.43 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Farapulse and the Pulsed Field Ablation Wave. The Farapulse pulsed field ablation (PFA) system is the single most important growth driver, helping the electrophysiology business post roughly 37% year-over-year growth in the fourth quarter of 2025. The most optimistic analyst target on BSX is $106.00, +128.3% from the $46.43 price. That figure is only reachable if this thesis works close to its best case.

The most immediate concern flagged with 2026 guidance was unanticipated headwinds in electrophysiology, Watchman, and urology, which prompted management to frame organic growth guidance of 6.5% to 8%, below the pace of recent years and a signal that the newest franchises may be decelerating from peak growth rates. Competition is intensifying as Medtronic and Johnson and Johnson scale their own pulsed field ablation systems, which could erode Boston Scientific's early PFA share and pressure pricing. The stock has historically carried a premium valuation, so any slowdown in the growth narrative can trigger outsized share-price reactions, as seen in a sharp post-earnings selloff. Foreign exchange swings, hospital capital-spending cycles, product-recall or safety-signal risk inherent to implantable devices, and reimbursement or regulatory changes each add uncertainty. Integration risk from the company's ongoing acquisition strategy is a further variable that can affect margins and management focus. The most pessimistic published target is $55.00, +18.5% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Boston Scientific Corporation is a Marlborough, Massachusetts-based medical device company that develops, manufactures, and markets minimally invasive devices used in interventiona

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Farapulse and the Pulsed Field Ablation Wave) stalling in the reported numbers rather than in the narrative, the risk above (the most immediate concern flagged with 2026 guidance was unanticipated headwinds in electrophysiology, Watchman, and urology, which prompted management to frame organic growth guidance of 6.5% to 8%, below the pace of recent years and a signal that the newest franchises may be decelerating from peak growth rates) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Boston Scientific develops and sells minimally invasive medical devices used in interventional cardiology, electrophysiology, structural heart, peripheral interventions, endoscopy, urology, and neuromodulation. It reports through two segments, Cardiovascular and MedSurg, and sells to hospitals and physicians in roughly 130 countries. Its highest-profile products include the Farapulse pulsed field ablation system and the Watchman heart-implant device.

That depends on your horizon and risk tolerance. Boston Scientific is still growing earnings at a guided 9% to 11% for 2026 and trades at roughly 18x trailing earnings, well below its historical premium after a sharp share-price decline. However, management flagged decelerating growth in electrophysiology, Watchman, and urology, and competition in pulsed field ablation is intensifying. Investors weigh those trade-offs differently.

Boston Scientific has historically reinvested cash into research, development, and acquisitions rather than paying a regular dividend, positioning itself as a growth-oriented medical device company. Investors in BSX have generally sought total return from share-price appreciation rather than income. Always confirm the current dividend policy with your broker or the company's investor relations page before investing.